Kisspeptin-54

Kisspeptin-54 is a 54-amino-acid endogenous peptide encoded by the human KISS1 gene. It binds the KISS1R receptor on hypothalamic neurons, where it triggers gonadotropin-releasing hormone (GnRH) release and downstream pituitary secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The Imperial College London group has run Phase 1 and Phase 2 trials in male and female reproductive disorders. The compound is not approved for any indication.

The KISS1 gene was identified in 1996 in a search for genes that suppress melanoma metastasis, hence the original name "metastin." The role in reproduction emerged in 2003, when independent groups discovered that loss-of-function mutations in KISS1R caused hypogonadotropic hypogonadism. That clinical observation established kisspeptin as the master upstream regulator of GnRH pulse generation. The molecule is processed from a 145-amino-acid precursor (preprokisspeptin) into several active fragments. The two main research forms are Kisspeptin-54 (the full processed peptide) and Kisspeptin-10 (the shorter C-terminal fragment, which retains receptor affinity).

The clinical development trajectory has been led by Waljit Dhillo's group at Imperial College London. Their work spans more than two decades and includes physiology studies in healthy volunteers and proof-of-concept trials in patients with reproductive disorders. The 2005 paper by Dhillo and colleagues was the first to demonstrate LH release after kisspeptin-54 administration in healthy men.

The Human Evidence

The clinical evidence base is unusually robust for an investigational peptide. Trial highlights include:

Hypogonadal men (Dhillo et al., 2005). Single-dose subcutaneous kisspeptin-54 produced clear LH responses in healthy male volunteers, establishing pharmacological activity in humans.

Female infertility (Jayasena et al., 2014). A trial of twice-weekly kisspeptin-54 in women with hypothalamic amenorrhea documented restoration of LH pulsatility and induced ovarian follicular development in a subset of participants. Sample size was modest; results were heterogeneous across the cohort.

IVF oocyte trigger (Abbara et al., 2017). Phase 2 trial of kisspeptin-54 as a final oocyte maturation trigger in IVF cycles. The compound triggered oocyte maturation with a substantially lower risk of ovarian hyperstimulation syndrome compared with conventional hCG trigger.

Mechanism studies in healthy volunteers. Multiple physiology studies have characterized dose-response, route-of-administration comparisons (IV vs SC), and effects on libido and sexual brain activation in functional MRI. The 2017 paper by Comninos and colleagues reviewed kisspeptin's effects on reproductive physiology and neural correlates of sexual arousal.

The cumulative dataset puts Kisspeptin-54 in early-clinical territory rather than preclinical-only. Phase 3 trials and a regulatory submission have not been completed.

Regulatory and Legal Status

FDA. Investigational. No approval for any indication. Clinical use is restricted to participation in registered trials.

EMA. Investigational. No approval.

Compounding. Not on the FDA bulk drug substances list. Compounding pharmacies are not authorized to produce kisspeptin-54 for clinical use.

WADA. Not on the 2026 Prohibited List. The mechanism (endogenous LH and testosterone elevation in men) means athletes should treat use with caution and verify status with their sport governing body.

Kisspeptin-54 binds the KISS1R receptor (a G-protein-coupled receptor formerly known as GPR54) expressed predominantly on hypothalamic GnRH neurons. Receptor binding activates Gq signaling, increases intracellular calcium, and triggers GnRH pulse generation.

GnRH then travels through the hypothalamic-hypophyseal portal system to the anterior pituitary, where it binds GnRH receptors on gonadotrope cells and stimulates pulsatile release of LH and FSH. These gonadotropins act on the gonads (testes in men, ovaries in women) to drive testosterone production, spermatogenesis, follicular development, and estrogen synthesis.

The clinical leverage of kisspeptin sits upstream of Gonadorelin (synthetic GnRH) and pituitary trophic agents. Where exogenous GnRH directly stimulates the pituitary, kisspeptin stimulates the hypothalamus to release its own GnRH pulses. This has practical implications. In settings where hypothalamic GnRH pulse generation is impaired but downstream pathways are intact (hypothalamic amenorrhea, certain forms of male hypogonadotropic hypogonadism), kisspeptin can in principle restore physiological pulsatility in a way that exogenous GnRH cannot.

Pharmacokinetics. After subcutaneous bolus injection at typical Phase 2 doses, plasma kisspeptin-54 levels peak within 30 to 60 minutes. Elimination half-life is approximately 25 to 30 minutes. Metabolism proceeds through standard peptidase hydrolysis. Tissue distribution data in humans is limited.

Off-target activity. KISS1R is expressed in tissues outside the hypothalamus, including placenta, gonads, and some peripheral tissues. The clinical significance of peripheral receptor activation at trial doses has not been fully characterized.

Trial-documented effects of Kisspeptin-54 include:

• LH and FSH release in healthy men and women
• Restoration of LH pulsatility in women with hypothalamic amenorrhea
• Induction of ovarian follicular development in subsets of treated patients
• Final oocyte maturation in IVF cycles with reduced OHSS risk compared with hCG trigger
• Modulation of brain activity in regions associated with sexual arousal (fMRI studies)
• Testosterone elevation in hypogonadotropic hypogonadal men

The fMRI work on sexual arousal pathways is particularly notable. Kisspeptin appears to modulate central reward and limbic circuits associated with sexual desire, which suggests potential applications beyond reproductive endocrinology. This work is early and has not produced an approved indication for sexual dysfunction.

Off-label adult research use is uncommon for Kisspeptin-54 compared with research-chemical peptides like PT-141 because the compound is not widely available outside investigational settings.

The doses used in published clinical trials provide the most reliable reference. Doses reported in Phase 1 and Phase 2 studies range from approximately 0.1 nmol/kg to 9.6 nmol/kg as a subcutaneous bolus, with single-injection or short-course protocols.

For IVF trigger applications, Abbara et al., 2017 used kisspeptin-54 at 9.6 nmol/kg as a single subcutaneous injection administered 36 hours before oocyte retrieval. For hypothalamic amenorrhea, the Jayasena 2014 protocol used twice-weekly subcutaneous injection over 8 weeks at doses titrated by individual LH response.

Intravenous infusion has been used in pharmacology studies for precise dose-response characterization. Continuous infusion produces receptor desensitization and reduced LH response over time, mirroring the desensitization seen with continuous GnRH administration. Pulsatile or intermittent dosing preserves responsiveness.

No standardized human dosing protocol exists for off-label adult use of Kisspeptin-54. The compound is not available through compounding pharmacies in the US and is largely restricted to clinical trial settings. Research-chemical supply is uncommon compared with Kisspeptin-10.

Phase 1 and Phase 2 trial safety data document the following adverse-event profile:

• Injection site reactions (mild, transient)
• Headache (occasional)
• Mild nausea in a subset of participants
• Vasovagal-type responses at higher IV infusion doses
• No serious adverse events in the published Imperial College London trials

The favorable tolerability profile reflects the compound's mechanism: kisspeptin works upstream in the reproductive axis and triggers physiological pulsatility rather than supra-physiological hormone release. Acute toxicity has not been a feature of the published trial program.

The long-term safety profile of chronic kisspeptin administration in non-trial populations has not been established. Theoretical concerns specific to long-term high-dose use include:

• KISS1R desensitization with chronic administration, leading to loss of clinical effect
• Effects on reproductive cancers in tissues that express KISS1R
• Effects on placental KISS1R in early pregnancy (compound should not be administered to pregnant women outside of dedicated trial protocols)

Drug-drug interactions with other reproductive endocrine agents (clomiphene, hCG, GnRH agonists or antagonists) have not been systematically characterized in trials.

Kisspeptin-54 is most often compared with its shorter analog Kisspeptin-10. Kisspeptin-10 has similar receptor affinity but a much shorter half-life (~4 minutes vs ~25-30 minutes), which makes Kisspeptin-54 more practical for clinical protocols requiring sustained LH response.

For reproductive-axis stacks in clinical or research settings, kisspeptin is sometimes combined with Gonadorelin (synthetic GnRH) or with hCG for specific IVF trigger protocols, though combination use is investigational and typically restricted to clinical trial designs.

For male sexual health applications, kisspeptin's profile differs fundamentally from PT-141 and Oxytocin. PT-141 acts at central melanocortin receptors involved in sexual arousal; oxytocin modulates social and pair-bonding circuits. Kisspeptin's effects extend to limbic and reward circuits but are mediated upstream through reproductive axis activation. Direct head-to-head trial data is sparse.

The compound has no widespread off-label adult research-chemical use compared with research peptides like Melanotan II or PT-141, because supply is largely restricted to investigational settings.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.